	ed States Patent a	and Trademark Office	UNITED STATES DEPAR United States Patent and Address: COMMISSIONER F P.O. Box 1450 Alexandria, Virginia 223 www.uspto.gov	Trademark Office OR PATENTS
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/712,335	11/13/2003	Adolfo J. De Bold	14703-002001	1171
26161 75	90 09/28/2006		EXAM	INER
FISH & RICHARDSON PC P.O. BOX 1022 MINNEAPOLIS, MN 55440-1022			FORD, VANESSA L	
			ART UNIT	PAPER NUMBER
	-,		1645	
			DATE MAILED: 09/28/200	6

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	10/712,335	DE BOLD, ADOLFO J.			
Office Action Summary	Examiner	Art Unit			
	Vanessa L. Ford	1645			
The MAILING DATE of this communication Period for Reply					
A SHORTENED STATUTORY PERIOD FOR RE WHICHEVER IS LONGER, FROM THE MAILING - Extensions of time may be available under the provisions of 37 CF after SIX (6) MONTHS from the mailing date of this communication - If NO period for reply is specified above, the maximum statutory pe - Failure to reply within the set or extended period for reply will, by s Any reply received by the Office later than three months after the m earned patent term adjustment. See 37 CFR 1.704(b).	G DATE OF THIS COMMUNI R 1.136(a). In no event, however, may a 1. eriod will apply and will expire SIX (6) MOI tatute, cause the application to become A	CATION. reply be timely filed NTHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on <u>1</u>	1/13/03.				
	This action is non-final.				
<i>i</i>	ince this application is in condition for allowance except for formal matters, prosecution as to the merits is				
	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.				
Disposition of Claims					
4) Claim(s) is/are pending in the applic	cation.				
4a) Of the above claim(s) is/are with					
5) Claim(s) is/are allowed.					
6) Claim(s) is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) <u>1-23</u> are subject to restriction and	l/or election requirement.				
Application Papers					
9) The specification is objected to by the Exar	miner				
· · · ·		by the Examiner			
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including the co 11) The oath or declaration is objected to by the					
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) All b) Some * c) None of:					
1. Certified copies of the priority documents have been received.					
2. Certified copies of the priority documents have been received in Application No.					
3. Copies of the certified copies of the priority documents have been received in this National Stage					
application from the International Bureau (PCT Rule 17.2(a)).					
* See the attached detailed Office action for a	list of the certified copies not	t received.			
Attachment(s)					
1) I Notice of References Cited (PTO-892)	4) 🗌 Interview	Summary (PTO-413)			
2) D Notice of Draftsperson's Patent Drawing Review (PTO-948	) Paper No	(s)/Mail Date.			
<ol> <li>Information Disclosure Statement(s) (PTO/SB/08)</li> <li>Paper No(s)/Mail Date</li> </ol>	5) 🛄 Notice of 6) 🛄 Other:	Informal Patent Application			
S. Patent and Trademark Office	ce Action Summary	Part of Paper No./Mail Date 20060921			

## **Election/Restriction**

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 1-21 are drawn a method of assisting the diagnosis of cardiomyopathy, myocarditis or both comprising determining a level of brain natriuretic peptide (BNP), fragment of, atrial natriuretic peptde (ANF) or fragment of where an increase in the levels of BNP, ANF or both compared to the level in the control group is an indicator of a symptom of cardiomyopathy, myocarditis or both, classified in class 435, subclass 4.
  - II. Claim 22 is drawn a method of monitoring the effectiveness of a therapy for treating cardiomyopathy, myocarditis or both where a decrease in ANF, BNP or both in two or more samples over the period of time is an indicator of success of treatment, classified in class 435, subclass 4.
  - III. Claim 23 is drawn a method of assisting in the diagnosis of effectiveness of a therapy for treating cardiomyopathy, myocarditis or both where a increase in ANF, BNP or both in the sample as compared to the control group is a symptom of cardiomyopathy, myocarditis or both using specific fragments of BNP and ANF, classified in class 435, subclass 4.

Application/Control Number: 10/712,335 Art Unit: 1645

2. Groups I, II and III are related as different methods. They differ because they have different goals, require different method steps, parameters and use different components.

3. Because these inventions are distinct for the reasons given and have acquired a separate status in the art because of their recognized divergent subject matter as shown by their different classification, restriction for examination purposes as indicated is proper. Moreover, in the absence of restriction it would place an undue search and examination burden on the examiner.

4. Applicant is advised that the reply to this requirement to be complete must include an election of invention to be examined even though the requirement be traversed (37 CFR 1.143).

5. Applicant is reminded that upon that upon cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 C.F.R. 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 C.F.R. 1.48(b) and by the fee required under 37 C.F.R. 1.17(h).

## Conclusion

6. Any inquiry of the general nature or relating to the status of this general application should be directed to the Group receptionist whose telephone number is (571) 272–1600.

Papers relating to this application may be submitted to Technology Center 1600, Group 1640 by facsimile transmission. The faxing of such papers must conform with the notice published in the Office Gazette, 1096 OG 30 (November 15, 1989). Should applicant wish to FAX a response, the current FAX number for the Group 1600 is (571) 272-8300.

Any inquiry concerning this communication from the examiner should be directed to Vanessa L. Ford, whose telephone number is (571) 272-0857. The examiner can normally be reached on Monday – Friday from 9:00 AM to 6:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's acting supervisor, Albert Navarro, can be reached at (571) 272-0861.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <<u>http://pair-direct.uspto.gov./></u>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Vanessa L. Ford Biotechnology Patent Examiner September 21, 2006

NITA MINNHEHELD PRIMARY EXAMINER